Everest’s SPR206 Receives the NMPA’s IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections Published: Sept 24, 2021 | Tags: Everest, SPR206, NMPA, IND, Approval, MDR Gram-Negative Bacterial Infections […]readmore
Tags : Bayer
Shots: Gubra to receive ~ $253.4M as up front, development, and commercialization milestones The collaboration will combine Gubra’s peptide drug discovery capabilities with Bayer’s expertise to develop innovative medicines to […]readmore
Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020, the world witnessed a […]readmore
Shots: The P-IIb PAGANINI study involves assessing the efficacy, safety & tolerability of eliapixant (25, 75 or 150mg, bid) vs PBO in 310 patients with RCC for 12wks. and it […]readmore
Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis […]readmore
Shots: The company initiates P-III OASIS program to evaluate the efficacy and safety of elinzanetant (120mg, qd) in 1300 patients with vasomotor symptoms during menopause at 200+ centers across 20+ […]readmore
The US FDA has approved 6 NDAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and […]readmore
Medtronic to Acquire Intersect ENT for ~$1.1B Published: Aug 6, 2021 | Tags: Medtronic, Intersect ENT, ~$1.1B Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for […]readmore
Shots: Vividion to receive $1.5B up front & $500M milestone while Bayer to get full rights to Vividion’s discovery platform which consists of chemoproteomic screening technology, a data portal, and […]readmore
Shots: The P-IIb clinical trial involves evaluating the efficacy and safety of eliapixant (25/75/150mg, PO, bid) vs PBO in 300 patients with refractory chronic cough for 12wks. The trial met […]readmore